A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment

A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment

Publication date: Jun 07, 2019

The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine the recommended dose of relatlimab in combination with ipilimumab (for dose escalation) and to evaluate the safety, tolerability, and preliminary efficacy of the recommended dose of relatlimab in combination with ipilimumab versus ipilimumab monotherapy (for dose expansion).

Concepts Keywords
Antibody Bristol-Myers Squibb
Antigen Medicine
Biomarker Clinical medicine
Blood Organ systems
BRAF Ipilimumab
Bristol Myers Squibb Melanoma
Cooperative Group Nivolumab
Hepatitis Cancer immunotherapy
Histologically
HIV
Immunodeficiency
Ipilimumab
Melanoma
Metastatic
Monotherapy
Mutant
Patient Reported Outcomes
Pharmacodynamic
Pregnancy Test
Serum
Tolerability
Urine
Uveal Melanoma
Virus

Semantics

Type Source Name
pathway BSID Hepatitis C
disease DOID hepatitis C
disease MESH hepatitis C
gene UNIPROT STMN1
gene UNIPROT CTLA4
disease DOID acquired immunodeficiency syndrome
disease MESH acquired immunodeficiency syndrome
disease DOID uveal melanoma
disease MESH uveal melanoma
gene UNIPROT PROS1
gene UNIPROT BRAF
disease MESH Tumor
pathway BSID Programmed Cell Death
gene UNIPROT DLST
gene UNIPROT PDCD1
gene UNIPROT RPL17
pathway BSID Melanoma
disease DOID Melanoma
disease MESH Melanoma
drug DRUGBANK Ipilimumab
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
gene UNIPROT NR4A2
gene UNIPROT ALG3

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *